CASGEVY — Product revenues, net
Vertex Pharmaceuticals CASGEVY — Product revenues, net decreased by 21.0% to $42.9M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 202.1%, from $14.2M to $42.9M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful commercial rollout, patient access, and market adoption of the gene-editing therapy, while a decrease may signal competitive pressure, reimbursement challenges, or slower-than-expected patient uptake.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific gene-editing therapy product after ac...
Peer comparison
Comparable to revenue metrics for specialized orphan drugs or gene-editing therapies at other biotechnology firms, where early-stage commercialization often shows high growth rates as patient access expands.
vrtx_segment_casgevy_product_revenues_netHistorical Data
| Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $0 | $0 | $2M | $8M | $14.2M | $30.4M | $16.9M | $54.3M | $42.9M |
| QoQ Change | — | — | — | +300.0% | +77.5% | +114.1% | -44.4% | +221.3% | -21.0% |
| YoY Change | — | — | — | — | — | — | +745.0% | +578.8% | +202.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's casgevy — product revenues, net?
- Vertex Pharmaceuticals (VRTX) reported casgevy — product revenues, net of $42.9M in Q1 2026.
- How has Vertex Pharmaceuticals's casgevy — product revenues, net changed year-over-year?
- Vertex Pharmaceuticals's casgevy — product revenues, net increased by 202.1% year-over-year, from $14.2M to $42.9M.
- What does casgevy — product revenues, net mean?
- The total net sales revenue generated from the company's gene-editing therapy product.